ACAT1 and neoplasm: For example, preclinical data showed that inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) (158) or ACAT1 (Acetyl-CoA acetyltransferase 1) (100) can improve the anti-tumour effect of the anti-PD-1 antibody in multiple cancers.